ImmunityBio Hit by FDA Warning Sparks Lawsuit

ImmunityBio is in hot water after the FDA slapped them with a warning for misleading ads about their cancer therapy, Anktiva. This news led to a nosedive in their stock price, dropping 21% in one day. Now, investors who bought shares between January and March 2026 are joining a class-action lawsuit. What does it mean for you? If you invested in ImmunityBio during that period, you might want to check your emails and consider joining the lawsuit to recover your losses. If you're just a bystander, it's a reminder to double-check those biotech claims before investing.